Hemoglobin Oxygen Carrier Stability for Wound Healing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic wounds face challenges in healing due to oxygen deficiency, as existing treatments like hyperbaric oxygen therapy have decreasing effectiveness and oxygen carriers like hemoglobin solutions are prone to inactivation during preparation and storage, leading to instability and reduced oxygen transport capabilities.
Innovation Solution
A composition comprising hemoglobin or myoglobin with at least 40% of its oxygen binding sites charged with a non-O2 ligand, such as carbon monoxide or nitrogen monoxide, combined with stabilizers, preservatives, and other additives to create a stable and effective oxygen carrier for external wound treatment, which can be easily handled and stored.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hemoglobin solutions are used as oxygen carriers for wound treatment, then oxygen transport capability is improved, but stability during preparation and storage deteriorates due to inactivation
Solution Approach 1:
The patent changes the ligand binding state of hemoglobin from oxygen-bound to CO-bound or deoxy form to prevent oxidation and inactivation during storage. This parameter change (ligand type) maintains oxygen transport capability while dramatically improving stability during preparation and storage.
Solution Approach 2:
The patent applies preliminary action by pre-charging hemoglobin with CO or removing oxygen before storage to prevent oxidative inactivation. This preliminary protective measure ensures the hemoglobin remains stable and functional when needed for wound treatment.
2Reliability
If oxygen is supplied to wounds to promote healing, then wound healing is improved, but oxygen toxicity may occur
Solution Approach 1:
The patent uses CO-bound hemoglobin or deoxyhemoglobin as an intermediary oxygen carrier. These forms are non-toxic and can be safely applied to wounds, then release oxygen locally where needed. The intermediary form prevents systemic oxygen toxicity while delivering oxygen where it is needed for healing.
Solution Approach 2:
The patent implements local quality by delivering oxygen specifically to the wound site rather than systemically. The hemoglobin composition releases oxygen locally at the wound, providing high concentration where needed for healing while avoiding toxic effects in other parts of the body.
3Duration of action of stationary object
If oxygen carriers are stored for extended periods, then availability for treatment is improved, but inactivation and loss of oxygen transport capability worsen
Solution Approach 1:
The patent changes the oxidation state and ligand binding parameters of hemoglobin to CO-bound or deoxy forms, which are significantly more stable during storage. This parameter modification prevents oxidative inactivation and maintains oxygen transport capability throughout the storage period.
Solution Approach 2:
The patent converts the potential harm of oxygen exposure (oxidation and inactivation) into a benefit by using CO binding or oxygen removal during storage. The CO-bound or deoxy form is more stable, and oxygen is added back only when needed for treatment, turning storage stability into an advantage.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition provides enhanced wound healing by maintaining oxygen carrier stability, facilitating oxygen diffusion to wounds, and supporting healing even in chronic cases, with improved handling and storage properties compared to traditional methods.
Implementation Method 1
comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand
Implementation Method 2
facilitating oxygen diffusion to wounds
Data Source
AI summary
The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.